Semnur Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-4.3M | $-4.6M | $-6.2M | $-152.6M | $-999.0K | $-665.0K | $-167.3K | $-1.3M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $1.3M | $1.5M | $2.0M | $140.2M | $119.0K | $92.0K | — | — |
| Net Cash from Operating Activities | $-2.1M | $-2.7M | $-3.6M | $-2.1M | $268.0K | $-399.0K | $-1.4M | $-3.0M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $2.1M | $2.8M | $3.5M | $2.2M | $-220.0K | $394.0K | $1.4M | $3.2M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |